Pre-clinical and early-phase clinical studies have explored the efficacy of PI3K or AKT inhibitors, either alone or in combination with immunotherapies or VEGF-targeted agents, to enhance anti-tumor responses and overcome resistance [52,53]. The gene discussed is AKT1; the disease is neoplasm.